Therapy Detail

Therapy Name CH7057288
Synonym
Therapy Description

CH7057288 selectivity inhibits NTRK1, 2, and 3, resulting in decreased downstream signaling and potentially resulting in reduced growth of tumors harboring NTRK fusions (PMID: 30242093).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CH7057288 Trk Receptor Inhibitor (Pan) 23 CH7057288 selectivity inhibits NTRK1, 2, and 3, resulting in decreased downstream signaling and potentially resulting in reduced growth of tumors harboring NTRK fusions (PMID: 30242093).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ETV6-NTRK3 acute myeloid leukemia sensitive CH7057288 Preclinical - Cell line xenograft Actionable In a preclinical study, CH7057288 inhibited NTRK phosphorylation and downstream signaling and reduced growth of acute myeloid leukemia cells harboring ETV6-NTRK3 in culture, and induced tumor regression in xenograft models (PMID: 30242093). 30242093
Clinical Trial Phase Therapies Title Recruitment Status